Murat Kalayoglu - 02 Jan 2026 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: RNAC
Reported as of: 02 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jan 2026, 16:18:07 UTC
Prior SEC filing: 06 Jan 2025
Next SEC filing: 06 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew Bartholomae, Attorney-in-Fact for Murat Kalayoglu

Key filing fact

Murat Kalayoglu filed Form 4 for Cartesian Therapeutics, Inc. (RNAC) on 06 Jan 2026.

Key facts

This page summarizes Murat Kalayoglu's Form 4 filing for Cartesian Therapeutics, Inc. (RNAC).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jan 2026, 16:18.

Change

Previous filing in this sequence was filed on 06 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002000002 Primary reporting owner

Kalayoglu Murat

Relationship: Director, 10%+ Owner
Address: C/O CARTESIAN THERAPEUTICS, INC., 7495 NEW HORIZON WAY, FREDERICK
Signature: /s/ Matthew Bartholomae, Attorney-in-Fact for Murat Kalayoglu
Signature date: 06 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RNAC transaction

Common Stock

Award

Transaction value: $0
Shares: +2,600
Change %: +0.51%
Price: $0.000000
Shares after: 511,577
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1

RNAC holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 4,555,260
Date: 02 Jan 2026
Ownership: by trust
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RNAC transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +7,800
Change %
Price: $0.000000
Shares after: 7,800
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,800
Exercise price: $6.76

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.

Footnote F2

Shares are held in a trust (the "Trust") for the benefit of the reporting person's spouse and children. The reporting person's spouse is a trustee of the trust.